Fidaxomicin

Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses fidaxomicin (Dificid), 200 mg tablet for oral administration. Indication under consideration for reimbursement: Treatment of difficile infection for adult patients who have initial episode or first recurrence.